Table 1.
Baseline characteristics of the patients at time of recruitment.
| Rupatadine 40 mg N = 66 | Placebo N = 67 | |
|---|---|---|
| Age (mean, ± SD) | 34.3 (11.2) | 33 (11.3) |
| Sex | ||
| Male (%) | 53 (80.3) | 51 (76.1) |
| Female (%) | 13 (19.6) | 16 (23.9) |
| Duration of illness at time of recruitment | ||
| Median (IQR) | 4 (3 to 4) | 4 (3 to 4) |
| Mean (SD±) | 3.7 (0.7) | 3.7 (0.8) |
| ≤3 days | 17 (25.7) | 21 (31.3) |
| >3 days | 49 (74.2) | 46 (68.6) |
| Infecting DENV serotype | ||
| DENV1 (%) | 44 (66.6) | 46 (68.6) |
| DENV2 (%) | 6 (9.1) | 3 (4.5) |
| DENV3 (%) | 0 (0) | 0 (0) |
| DENV4 (%) | 7 (10.6) | 9 (13.4) |
| Negative (%) | 9 (13.6) | 9 (13.4) |
| Viral loads (pfu/ml) Median (IQR) | 2006 (15.93 to 45, 243) | 2722 (24.14 to 23,418) |
| Immune status | ||
| Primary (%) | 18 (27.3) | 14 (20.9) |
| Secondary (%) | 42 (63.6) | 47 (70.1) |
| Inconclusive (%) | 6 (9.1) | 6 (8.9) |
| Haematocrit (median, IQR) | 42 (39 to 44.8) | 42 (38 to 44) |
| Platelet count (median, IQR) | 112 (92.5 to 131.3) | 110 (92 to 135) |
| AST (median, IQR) | 76 (38.1 to 123.7) | 75.9 (53.8 to 145.1) |
| ALT (median, IQR) | 62 (29.7 to 110.1) | 66.2 (35.8 to 104) |